Literature DB >> 9331013

Dose-finding study of candesartan cilexetil plus hydrochlorothiazide in patients with mild to moderate hypertension.

T Philipp1, H Letzel, H J Arens.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9331013

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


× No keyword cloud information.
  6 in total

Review 1.  Candesartan cilexetil plus hydrochlorothiazide combination: a review of its use in hypertension.

Authors:  Ezequiel Balmori Melian; Blair Jarvis
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 2.  Candesartan cilexetil: a pharmacoeconomic review of its use in chronic heart failure and hypertension.

Authors:  Greg L Plosker; Susan J Keam
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

Review 3.  Candesartan cilexetil. A review of its use in essential hypertension.

Authors:  K J McClellan; K L Goa
Journal:  Drugs       Date:  1998-11       Impact factor: 9.546

4.  Combination therapy with candesartan cilexetil 32 mg and hydrochlorothiazide 25 mg provides the full additive antihypertensive effect of the components: A randomized, double-blind, parallel-group study in primary care.

Authors:  Istvan Edes
Journal:  Clin Drug Investig       Date:  2009       Impact factor: 2.859

5.  Comparison of candesartan and felodipine alone and combined in the treatment of hypertension: a single-center, double-blind, randomized, crossover trial.

Authors:  Sanem Nalbantgil; Mehdi Zoghi; Filiz Ozerkan; Bahar Boydak; Istemi Nalbantgil; Remzi Onder; Mustafa Akin
Journal:  Curr Ther Res Clin Exp       Date:  2003-07

6.  Candesartan cilexetil/hydrochlorothiazide combination treatment versus high-dose candesartan cilexetil monotherapy in patients with mild to moderate cardiovascular risk (CHILI Triple T).

Authors:  Gerd Bönner; Bernhard Landers; Peter Bramlage
Journal:  Vasc Health Risk Manag       Date:  2011-02-17
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.